Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3
PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan…
Pharmaceuticals, Biotechnology and Life Sciences
PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan…
PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan…
—Researchers Report Substantial Oxalate Reduction Following Single-Dose Administration of DCR-PHXC in Additional Patients with PH2— —Enrollment Underway in Pivotal PHYOX2…
—Researchers Report Substantial Oxalate Reduction Following Single-Dose Administration of DCR-PHXC in Additional Patients with PH2— —Enrollment Underway in Pivotal PHYOX2…
–(BUSINESS WIRE)–AMPLEXOR Life Sciences: MEDIA ADVISORY: The DIA 2019 Global Annual Meeting will host more than 7,000 professionals in the…
–(BUSINESS WIRE)–AMPLEXOR Life Sciences: MEDIA ADVISORY: The DIA 2019 Global Annual Meeting will host more than 7,000 professionals in the…
Steven Horwitz, MD, Gives Oral Presentation Highlighting Phase 1 Duvelisib Data in Patients with Relapsed or Refractory PTCL Data from…
Steven Horwitz, MD, Gives Oral Presentation Highlighting Phase 1 Duvelisib Data in Patients with Relapsed or Refractory PTCL Data from…
Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.
Abzena, the leading global biologics and ADC target partner research organization, announced it has appointed Andrew Kraus as Chief Technology Officer (CTO) and Philip Payne as Chief Commercial Officer (CCO).